This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by García-Lerma, J. G.
Right arrow Articles by Heneine, W.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by García-Lerma, J. G.
Right arrow Articles by Heneine, W.

Next Article 

Journal of Virology, October 2000, p. 9339-9346, Vol. 74, No. 20
0022-538X/00/$04.00+0

Evidence of a Role for the Q151L Mutation and the Viral Background in Development of Multiple Dideoxynucleoside-Resistant Human Immunodeficiency Virus Type 1

J. Gerardo García-Lerma,1 Philip J. Gerrish,2 Anthony C. Wright,1 Shoukat H. Qari,1 and Walid Heneine1,*

HIV/AIDS and Retrovirology Branch, Division of AIDS, STD, and TB Laboratory Research, National Center for Infectious Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia,1 and Theoretical Biology and Biophysics Group, Los Alamos National Laboratory, Los Alamos, New Mexico2

Received 12 April 2000/Accepted 18 July 2000

The majority of human immunodeficiency virus type 1 (HIV-1)-infected patients treated with zidovudine (AZT) plus zalcitabine (ddC) and didanosine (ddI) develop AZT resistance mediated by mutations such as T215Y and M41L. Only a small proportion of patients develop multiple dideoxynucleoside resistance (MDNR) mediated by the Q151M mutation. To gain insight into the factors responsible for the low frequency of selection of Q151M, we evaluated the replication capabilities of recombinant viruses carrying two possible intermediates (151L or 151K) of the Q151M mutation generated in different reverse transcriptase (RT) genetic backgrounds. The 151L and 151K mutations were introduced by site-directed mutagenesis in RTs from two patient-derived HIV-1 isolates that had either wild type (WT) Q or the Q151M (posttreatment isolate) mutation. For comparison, both mutations were also introduced in a laboratory-adapted HIV-1 strain (HIV-1HXB2). Analysis of replication capabilities showed that both 151L and 151K were lethal in RT genetic backgrounds of the WT isolate and in HIV-1HXB2. In contrast, 151L but not 151K allowed virus replication in RT backgrounds of the posttreatment isolate. Three mutations (V35I, S68G, and I178M) were present in the RT background of the posttreatment isolate but not in the WT isolate. Introduction of S68G in the RT of both the WT isolate and HIV-1HXB2 partially restored replication capacity of recombinants carrying the 151L mutation. The S68G mutation alone did not confer a significant replicative disadvantage in WT viruses. Like HIV-1151M, HIV-1151L RT was found to have six- to eightfold resistance to AZT-triphosphate (TP), ddA-TP, and ddC-TP, indicating an MDNR phenotype. However, HIV-1151L was found to be less fit than HIV-1151M, which may explain the preferential selection of HIV-1151M observed in vivo. The demonstrated ability of HIV-1151L/68G to replicate and the associated MDNR suggest that 151L is a potential intermediate of Q151M. The dependence of HIV-1151L on other mutations, such as S68G, for replication may explain the low frequency of the Q151M-mediated pathway of resistance.

* Corresponding author. Mailing address: HIV/AIDS and Retrovirology Branch, Centers for Disease Control and Prevention, 1600 Clifton Rd., N.E., MS G-19, Atlanta, GA 30333. Phone: (404) 639-0218. Fax: (404) 639-1174. E-mail: wmh2{at}cdc.gov.

Journal of Virology, October 2000, p. 9339-9346, Vol. 74, No. 20
0022-538X/00/$04.00+0


This article has been cited by other articles:

  • Dykes, C., Demeter, L. M. (2007). Clinical Significance of Human Immunodeficiency Virus Type 1 Replication Fitness. Clin. Microbiol. Rev. 20: 550-578 [Abstract] [Full Text]  
  • Jallow, S., Kaye, S., Schutten, M., Brandin, E., Albert, J., McConkey, S. J., Corrah, T., Whittle, H., Vanham, G., Rowland-Jones, S., Janssens, W. (2007). Development and Evaluation of an Oligonucleotide Ligation Assay for Detection of Drug Resistance-Associated Mutations in the Human Immunodeficiency Virus Type 2 pol Gene. J. Clin. Microbiol. 45: 1565-1571 [Abstract] [Full Text]  
  • Cong, M.-e., Heneine, W., Garcia-Lerma, J. G. (2007). The Fitness Cost of Mutations Associated with Human Immunodeficiency Virus Type 1 Drug Resistance Is Modulated by Mutational Interactions. J. Virol. 81: 3037-3041 [Abstract] [Full Text]  
  • Delaunay, C., Brun-Vezinet, F., Landman, R., Collin, G., Peytavin, G., Trylesinski, A., Flandre, P., Miller, M., Descamps, D., the Tonus Trial Study Group, (2005). Comparative Selection of the K65R and M184V/I Mutations in Human Immunodeficiency Virus Type 1-Infected Patients Enrolled in a Trial of First-Line Triple-Nucleoside Analog Therapy (Tonus IMEA 021). J. Virol. 79: 9572-9578 [Abstract] [Full Text]  
  • Garcia-Lerma, J. G., MacInnes, H., Bennett, D., Weinstock, H., Heneine, W. (2004). Transmitted Human Immunodeficiency Virus Type 1 Carrying the D67N or K219Q/E Mutation Evolves Rapidly to Zidovudine Resistance In Vitro and Shows a High Replicative Fitness in the Presence of Zidovudine. J. Virol. 78: 7545-7552 [Abstract] [Full Text]  
  • Deval, J., White, K. L., Miller, M. D., Parkin, N. T., Courcambeck, J., Halfon, P., Selmi, B., Boretto, J., Canard, B. (2004). Mechanistic Basis for Reduced Viral and Enzymatic Fitness of HIV-1 Reverse Transcriptase Containing Both K65R and M184V Mutations. J. Biol. Chem. 279: 509-516 [Abstract] [Full Text]  
  • Weber, J., Rangel, H. R., Chakraborty, B., Tadele, M., Martinez, M. A., Martinez-Picado, J., Marotta, M. L., Mirza, M., Ruiz, L., Clotet, B., Wrin, T., Petropoulos, C. J., Quinones-Mateu, M. E. (2003). A novel TaqMan real-time PCR assay to estimate ex vivo human immunodeficiency virus type 1 fitness in the era of multi-target (pol and env) antiretroviral therapy. J. Gen. Virol. 84: 2217-2228 [Abstract] [Full Text]  
  • Garcia-Lerma, J. G., MacInnes, H., Bennett, D., Reid, P., Nidtha, S., Weinstock, H., Kaplan, J. E., Heneine, W. (2003). A Novel Genetic Pathway of Human Immunodeficiency Virus Type 1 Resistance to Stavudine Mediated by the K65R Mutation. J. Virol. 77: 5685-5693 [Abstract] [Full Text]  
  • Garcia-Lerma, J. G., Heneine, W. (2002). Rapid biochemical assays for phenotypic drug resistance testing of HIV-1. J Antimicrob Chemother 50: 771-774 [Full Text]  
  • Deval, J., Selmi, B., Boretto, J., Egloff, M. P., Guerreiro, C., Sarfati, S., Canard, B. (2002). The Molecular Mechanism of Multidrug Resistance by the Q151M Human Immunodeficiency Virus Type 1 Reverse Transcriptase and Its Suppression Using alpha -Boranophosphate Nucleotide Analogues. J. Biol. Chem. 277: 42097-42104 [Abstract] [Full Text]  
  • Garcia-Lerma, J. G., Nidtha, S., Blumoff, K., Weinstock, H., Heneine, W. (2001). Increased ability for selection of zidovudine resistance in a distinct class of wild-type HIV-1 from drug-naive persons. Proc. Natl. Acad. Sci. USA 10.1073/pnas.241300698v1 [Abstract] [Full Text]  
  • Garcia-Lerma, J. G., Nidtha, S., Blumoff, K., Weinstock, H., Heneine, W. (2001). From the Cover: Increased ability for selection of zidovudine resistance in a distinct class of wild-type HIV-1 from drug-naive persons. Proc. Natl. Acad. Sci. USA 98: 13907-13912 [Abstract] [Full Text]  


Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»